CLNN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CL

Mkt Cap

$44.3M

Volume

200.20K

Next Earnings

November 12th

Loading chart

CL

CLNNClene Inc. Common Stock

CLNN

Pay with—

Available Balance0.00

CL

Mkt Cap

$44.1M

Volume

200.20K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 CatalystsClene Inc. announced key 2026 milestones for its investigational ALS drug CNM-Au8, including an FDA Type C meeting by Q1 2026, NDA submission via accelerated pathway in Q2 2026, and potential PDUFA date in H2 2026. The company secured $28 million in funding with runway into Q4 2026, and plans to initiate a Phase 3 confirmatory trial later in 2026. CNM-Au8 has demonstrated prolonged survival benefits and favorable safety profile across over 800 treated ALS patients.GlobeNewswire Inc. · Feb 24, 2026

Clene to Provide CNM-Au8® ALS Program UpdateClene Inc. will host an investor call and webcast on December 3, 2025, to provide an update on its CNM-Au8 program for treating amyotrophic lateral sclerosis (ALS). The company is a late clinical-stage biopharmaceutical firm focused on neurodegenerative disease treatments.GlobeNewswire Inc. · Dec 2, 2025

Clene Posts 70% Revenue Drop in Q2Clene, a clinical-stage biopharmaceutical company, reported a net loss of $(0.78) per share in Q2 2025, with minimal revenue of $27,000. The company continues advancing its CNM-Au8 therapy for neurodegenerative diseases while managing tight cash resources.The Motley Fool · Aug 14, 2025

Clene to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceClene Inc., a clinical-stage biopharmaceutical company, announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings on September 9, 2024.GlobeNewswire Inc. · Sep 3, 2024

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswireThe 73rd Emerging Growth Conference is scheduled for July 17-18, 2024, featuring presentations from various companies in the healthcare, technology, and energy sectors.GlobeNewswire Inc. · Jul 17, 2024

Crude Oil Down 1%; Soligenix Shares Surge - Helen Of Troy (NASDAQ:HELE) - BenzingaCrude oil prices declined by 1%, while shares of Soligenix surged 282% after the company announced positive interim results for its HyBryte treatment. Helen of Troy reported soft Q1 earnings and lowered its FY25 guidance, leading to a 30% drop in its stock price.Benzinga · Jul 9, 2024

Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual ConferenceSALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference and host 1x1 investor meetings.GlobeNewswire Inc. · Jun 24, 2024

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett SyndromeSALT LAKE CITY, June 21, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it presented new, preliminary data demonstrating the potential of CNM-Au8 as a treatment for Rett Syndrome. Karen Ho, Ph.D., Clene’s vice president of translational medicine, unveiled the data in oral and poster presentations on June 19th at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado. The presentation was titled, “CNM-Au8, a Candidate First-in-Class Nanotherapeutic for Treatment of Rett Syndrome.”GlobeNewswire Inc. · Jun 21, 2024

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS MeetingSALT LAKE CITY, June 18, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today presented new long-term CNM-Au8 treatment results for survival and neurofilament light (NfL) levels from the HEALEY ALS Platform Trial open label extension (OLE) at the European Network for the Cure of ALS (ENCALS) meeting in Stockholm, Sweden.GlobeNewswire Inc. · Jun 18, 2024

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced several key updates on its National Institutes of Health (NIH)-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8® compassionate use in ALS.GlobeNewswire Inc. · May 28, 2024

to start trading

CL

CLNNClene Inc. Common Stock

CLNN

Pay with—

Available Balance0.00

Your PositionYou don't own any CLNN yet.

Related Tickers

Earnings